|
122
|
| 463 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
GSK3B
|
|
| 570 |
Lithium
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
11527574
|
Alzheimer disease
|
|
457
|
| 2073 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
Alzheimer disease
|
|
| 2076 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
GSK3B
|
|
|
19712582
|
Alzheimer disease
|
|
574
|
| 3050 |
GSK3B
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
|
17298085
|
Alzheimer disease
|
|
614
|
| 3248 |
PSEN1
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
| 3294 |
canonical Wnt signaling pathway
|
|
decreases_quantity of
|
CTNNB1-phosSer33Ser37Thr41
|
(= sequentially phosphorylated CTNNB1 at sites 33,37,41)
|
| 3299 |
canonical Wnt signaling pathway
|
NOT |
decreases_quantity of
|
CTNNB1-phosSer45
|
|
| 45038 |
CTNNB1
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
12297048
|
Alzheimer disease
|
|
710
|
| 3950 |
PRKN
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
| 3953 |
WNT3A
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
| 3955 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
dopaminergic neuron differentiation
|
|
| 3966 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
re-entry into mitotic cell cycle
|
in differentiated ventral midbrain neurons
|
|
19591802
|
Parkinson disease
|
|
715
|
| 3985 |
PRKN
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
in ventral midbrain dopaminergic neurons
|
|
19591802
|
Parkinson disease
|
|
824
|
| 5007 |
canonical Wnt signaling pathway
|
|
decreases_activity of
|
white fat cell differentiation
|
|
| 5010 |
canonical Wnt signaling pathway
|
|
decreases_activity of
|
PPARG
|
|
|
19770177
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,347
|
| 9202 |
SFRP5
|
NOT |
affects_activity of
|
canonical Wnt signaling pathway
|
in epididymal adipose tissues; after high-fat high-sucrose diet
|
|
20558665
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
2,532
|
| 23582 |
TCF7L2 variant B1
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
in pancreas, in pancreatic islets
|
| 23586 |
TCF7L2 variant B3
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
in pancreas, in pancreatic islets
|
| 23587 |
TCF7L2 variant B7
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
in pancreas, in pancreatic islets
|
|
21357677
|
Diabetes mellitus, type II
Insulin resistance
|
|
2,759
|
| 25529 |
ZBED3
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
19141611
|
Diabetes mellitus, type II
Insulin resistance
|
|
3,632
|
| 34487 |
NR1H4
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
|
21431855
|
Diabetes mellitus, type II
Obesity
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
4,308
|
| 44132 |
canonical Wnt signaling pathway
|
|
increases_quantity of
|
APP (intracellular domain AICD)
|
due to the increased protein stability by Wnt/beta-catenin
|
| 44139 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
APP (intracellular domain AICD)
|
concerning the transcriptional activity of AICD
|
| 44600 |
WNT1
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
21798242
|
Metabolic
|
|
4,309
|
| 44903 |
MTOR
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
in H9 cells
|
|
19416884
|
Metabolic
|
|
4,327
|
| 44751 |
Lovastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
to reduce the effect of Abeta (42)
|
|
17234346
|
Alzheimer disease
Metabolic
|
|
4,333
|
| 44333 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
AHR
|
if AhR RNA is up-regulated;
|
|
15059908
|
Prostate cancer
Metabolic
|
|
4,335
|
| 44356 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
CYP1A1
|
the induction is supported by AHR
|
| 44357 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
CYP1B1
|
the induction is supported by AHR
|
| 44363 |
WNT3A
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 44439 |
AHR
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
by reducing mRNA levels of Wnt/beta-Catenin target genes and disrupting cytokeratin expression pattern
|
| 44472 |
2,3,7,8-Tetrachlorodibenzodioxin
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
|
21602191
|
Metabolic
|
|
4,409
|
| 44811 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
MTOR
|
synaptic stimulation of mTOR is mediated by Wnt signaling
|
| 44817 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
MTOR
|
|
| 44823 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
GSK3B
|
|
| 44924 |
canonical Wnt signaling pathway
|
|
decreases_activity of
|
Beta-catenin destruction complex
|
if the canonical pathway is activated;
|
|
22131415
|
Metabolic
|
|
4,538
|
| 45192 |
WNT2
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
|
23043943
|
Metabolic
|
|
4,563
|
| 45524 |
CTNNB1
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 53316 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
embryo development
|
|
|
19619488
|
Metabolic
|
|
5,262
|
| 51318 |
Estradiol
|
NOT |
affects_activity of
|
canonical Wnt signaling pathway
|
in MPCs (mesenchymal progenitor cells)
|
|
24340027
|
Metabolic
|
|
5,266
|
| 51321 |
Simvastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 51324 |
Statin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
through regulation of isoprenoid synthesis and not through cholesterol
|
| 51327 |
isoprenoid biosynthetic process
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
if regulated via statins
|
| 51332 |
Cholesterol
|
NOT |
affects_activity of
|
canonical Wnt signaling pathway
|
via statins
|
| 51338 |
Lovastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 51339 |
Fluvastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 51343 |
Simvastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
in the mammalian adult hippocampus; via depletion of isoprenoids and not cholesterol
|
| 51348 |
HMGCR
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
HMGCR loss of function is sufficient to enhance the Wnt pathway.
|
| 51477 |
Geranylgeranyl pyrophosphate
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
in the mammalian adult hippocampus; via depletion of isoprenoids and not cholesterol
|
| 51478 |
Farnesyl pyrophosphate
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
|
24511465
|
Alzheimer disease
Metabolic
|
|
5,399
|
| 52696 |
Simvastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
if decreased by high glucose
|
| 52697 |
high glucose medium
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
|
|
18004065
|
Diabetes mellitus, type II
Insulin resistance
Nephropathy, diabetic
|
|
5,410
|
| 52803 |
hyperglycemia
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 52806 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
Cancer
|
|
| 52808 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
fat cell differentiation
|
|
| 52809 |
canonical Wnt signaling pathway
|
|
affects_activity of
|
Obesity
|
|
| 52810 |
TCF7L2
|
|
affects_activity of
|
canonical Wnt signaling pathway
|
|
| 52811 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
incretin hormone biosynthetic process
|
|
| 52813 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
GIPR
|
|
| 52814 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
incretin hormone signaling
|
|
| 52815 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
INS
|
|
| 52816 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
insulin secretion
|
|
| 52817 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
INSR
|
|
| 52818 |
canonical Wnt signaling pathway
|
|
increases_expression of
|
IGF1R
|
|
| 52822 |
canonical Wnt signaling pathway
|
|
increases_transport of
|
CTNNB1
|
into the nucleus; amplified by hyperglycemia
|
|
24049067
|
Diabetes mellitus, type II
Cancer
Insulin resistance
|
|
5,411
|
| 52758 |
Melanin-concentrating hormone
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
in mouse
|
|
22848656
|
Metabolic
|
|
5,412
|
| 52842 |
Simvastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
in embryonic stem cells
|
| 52843 |
canonical Wnt signaling pathway
|
|
increases_activity of
|
osteogenic differentiation
|
in embryonic stem cells
|
|
22058016
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
5,413
|
| 52880 |
Pravastatin
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
24510055
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,414
|
| 52882 |
APP (intracellular domain AICD)
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
if induced by LRP6, Dishevelled1/2/3 and beta-catenin wild-type (wt);
|
|
22613765
|
Metabolic
|
|
5,417
|
| 52894 |
LRP5 rs121908665
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
the effective allele is T (TGG=Trp)
|
| 52913 |
LRP5 rs61889560
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
the effective allele is A (CAG=Gln)
|
| 52914 |
LRP5 rs369471051
|
NOT |
affects_activity of
|
canonical Wnt signaling pathway
|
|
|
19673927
|
Diabetes mellitus, type II
Insulin resistance
|
|
5,425
|
| 52979 |
Peroxynitrite
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 52980 |
Urate
|
|
decreases_activity of
|
canonical Wnt signaling pathway
|
if Wnt signaling is induced by peroxynitrite
|
| 52988 |
4-Hydroxynonenal
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 52997 |
hyperglycemia
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
23066786
|
Diabetes mellitus, type II
Insulin resistance
Retinopathy, diabetic
|
|
5,427
|
| 52965 |
IRS1
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
| 52966 |
IRS2
|
|
increases_activity of
|
canonical Wnt signaling pathway
|
|
|
24616100
|
Metabolic
|
CIDeRplus